$BNTX (+6,37 %) | Biontech Earnings Q3 '24:

• Net profit €198.1m, EPS €0.81
• Revenue €1.2b
• Cash & cash equivalents €17.8b
• Successfully launched variant-adapted COVID-19 vaccines, initiated Phase 2 trials for cancer treatments
• Low end of full year '24 revenue guidance (€2.5-3.1b)